{"id":13642,"date":"2026-05-09T18:40:32","date_gmt":"2026-05-09T16:40:32","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=13642"},"modified":"2026-05-09T18:40:39","modified_gmt":"2026-05-09T16:40:39","slug":"millionaire-maker-biotech-stock-is-it-a-smart-buy-now","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/","title":{"rendered":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now?"},"content":{"rendered":"<p><\/p>\n<div id=\"article-body\">\n<p><span>If you invested $20,000 in <b>Vertex Pharmaceuticals<\/b> <span class=\"ticker-mention inline-flex items-center font-bold\" data-id=\"206020\">(VRTX <span class=\"ml-1 text-red-900\">1.26%<\/span>)<\/span> during its IPO in 1991 and retained your shares, your investment would have grown to over $1 million today. This impressive growth is attributed to the company&#8217;s robust 14% compound annual growth rate, significantly outperforming the <b>S&amp;P 500<\/b>&#8216;s 11% over the same timeline.<\/span><span> Sustaining such a remarkable growth rate for more than three decades is commendable. However, the pressing question remains: can Vertex Pharmaceuticals continue to excel in the future?<\/span><\/p>\n<div class=\"image\"><img decoding=\"async\" alt=\"Vertex Pharmaceuticals logo.\" loading=\"lazy\" width=\"880\" height=\"587\" data-nimg=\"1\" class=\"h-auto max-w-full rounded object-contain\" style=\"color:transparent\" src=\"https:\/\/g.foolcdn.com\/image\/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F868330%2Fvertex-pharmaceuticals-logo.png&amp;w=3840&amp;op=resize\" \/><\/div>\n<p class=\"caption\">Image source: The Motley Fool.<\/p>\n<\/div>\n<p><!-- Authority Ninja Box START --><br \/>\n<!--authority-ninja-box--><\/p>\n<div class=\"authority-ninja-box\" data-authority-ninja=\"1\" style=\"border: 1px solid #ccc;border-radius: 20px;padding: 16px;background-color: #f9f9f9;margin-bottom: 24px\">\n<div class=\"an-headline\"><strong>Oxford Wise Finance<\/strong><\/div>\n<div class=\"an-context\" style=\"font-size:13px;opacity:0.9\">Personal Finance Guides \u2014 Credit, Loans &amp; Budgeting \u00b7 oxfordwisefinance.com<\/div>\n<div class=\"an-note\" style=\"margin-top:6px\">Millionaire-Maker Biotech Stock highlights the checks that usually decide the result. To avoid surprises, confirm timing, requirements, and trade-offs; before you commit, confirm the terms in writing. It helps you pick a sensible option and skip dead ends.<\/div>\n<\/div>\n<p><!-- Authority Ninja Box END --><\/p>\n<h2 class=\"my-6 text-2xl font-bold\">Understanding Recent Challenges Faced by Vertex Pharmaceuticals<\/h2>\n<p><span>Vertex Pharmaceuticals has established itself as a leader in the biotechnology sector, particularly due to its innovation in developing treatments for cystic fibrosis (CF), a rare genetic condition characterized by the build-up of thick, sticky mucus in the lungs. This condition leads to severe respiratory complications among patients. Vertex Pharmaceuticals stands out as the sole prominent entity in this specialized market, with a comprehensive portfolio of CF medications that have evolved significantly over the years, allowing the company to treat around 95% of CF patients in the United States.<\/span><\/p>\n<p><span>However, despite Vertex&#8217;s advancements in this critical area, the company&#8217;s revenue growth has been experiencing a decline. In the first quarter, Vertex reported an 8% increase in revenue year-over-year, totaling $2.99 billion. While this figure may not be alarming, it reflects a broader downward trend in revenue growth that Vertex Pharmaceuticals has faced in recent years.<\/span><\/p>\n<p><span><img data-recalc-dims=\"1\" decoding=\"async\" alt=\"VRTX Revenue (Quarterly YoY Growth) Chart\" loading=\"lazy\" width=\"720\" height=\"441\" data-nimg=\"1\" class=\"h-auto max-w-full rounded object-contain\" style=\"color:transparent;max-width:720px\" src=\"https:\/\/i0.wp.com\/media.ycharts.com\/charts\/6c6d38bb1aef91c0a566b153690d24b0.png?resize=720%2C441&#038;ssl=1\" \/><\/span><\/p>\n<p>VRTX Revenue (Quarterly YoY Growth) data by YCharts<\/p>\n<p><span>Furthermore, despite Vertex Pharmaceuticals&#8217; efforts to diversify its product offerings and reduce reliance on its primary therapeutic area, these initiatives have not yet yielded significant success. As a result, Vertex has underperformed compared to broader market equities over the past three years.<\/span><\/p>\n<h2 class=\"my-6 text-2xl font-bold\">Identifying Positive Trends for Vertex Pharmaceuticals<\/h2>\n<p><span>In spite of its challenges in markets outside of CF, there are reasons to be optimistic about Vertex Pharmaceuticals&#8217; future. The company anticipates generating at least $500 million in revenue from non-CF products this year. This forecast is particularly important considering that in 2024, Vertex recorded only $10 million from non-CF revenue, which surged to $175.4 million last year.<\/span><\/p>\n<section class=\"shadow-card mb-[40px] border border-gray-300\">\n<div class=\"flex flex-wrap place-content-between\">\n<div class=\"flex w-full place-items-center lg:w-3\/4\">\n<div class=\"py-4 pr-4\"><img decoding=\"async\" alt=\"Vertex Pharmaceuticals Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\" src=\"https:\/\/g.foolcdn.com\/image\/?url=https%3A%2F%2Fg.foolcdn.com%2Fart%2Fcompanylogos%2Fmark%2FVRTX.png&amp;w=128&amp;op=resize\" \/><\/div>\n<\/div>\n<div class=\"flex w-full place-items-center lg:w-1\/4\">\n<div class=\"h-full w-5\/6 px-4 py-2.5 lg:text-right bg-red-200\">\n<p>Today&#8217;s Change<\/p>\n<p>(-1.26%) $-5.42<\/p>\n<p>Current Price<\/p>\n<p>$424.43<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"flex flex-wrap overflow-hidden transition-all duration-300 h-0\">\n<div class=\"w-full p-2 lg:w-1\/4 lg:p-4\">\n<h3 class=\"text-gray-1100 text-md my-[22px] leading-snug font-bold uppercase\">Key Data Points<\/h3>\n<div class=\"text-gray-1100 my-[14px] grid grid-cols-2 text-sm\">\n<p>Market Cap<\/p>\n<p>$108B<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$412.52 &#8211; $432.70<\/p>\n<p>52wk Range<\/p>\n<p>$362.50 &#8211; $507.92<\/p>\n<p>Volume<\/p>\n<p>103K<\/p>\n<p>Avg Vol<\/p>\n<p>1.4M<\/p>\n<p>Gross Margin<\/p>\n<p>87.68%<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<p><span>Looking ahead, prospects appear even brighter for Vertex Pharmaceuticals by 2027. The company is currently pursuing regulatory approval for Casgevy, a groundbreaking gene editing therapy aimed at treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in children aged five to eleven; Vertex co-markets Casgevy with <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/3-revolutionary-stocks-id-buy-right-now-without-hesitation\/\">CRISPR Therapeutics<\/a><\/b>. This therapy holds immense potential, as the median life expectancy for patients with SCD and TDT is 45 and 37 years respectively, underscoring the critical need for early treatment. Therefore, obtaining this expanded indication is vital for Vertex Pharmaceuticals.<\/span><span> <\/span><\/p>\n<p><span>In addition, Vertex is rapidly advancing towards securing approval for povetacicept, a promising therapy for IgA nephropathy (IgAN), a serious kidney disease. The success of povetacicept could serve as a significant catalyst for growth, especially if it receives approval for additional indications beyond IgAN. Moreover, even within the CF sector, Vertex is likely to continue innovating and developing new treatments for the remaining 5% of CF patients who are currently unaddressed by existing medications. In my opinion, Vertex Pharmaceuticals is poised to develop a more extensive and diversified product portfolio within the next few years, leading to enhanced revenue and earnings growth.<\/span><\/p>\n<p><span>Furthermore, Vertex&#8217;s established core CF business, which continues to show resilience, combined with its robust pipeline of potential therapies, indicates promising long-term prospects. For these compelling reasons, Vertex Pharmaceuticals appears to be a highly attractive investment opportunity at its current valuation levels.<\/span><\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.fool.com\/investing\/2026\/05\/06\/is-this-millionaire-maker-biotech-stock-a-buy-righ\/\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>If you invested $20,000 in Vertex Pharmaceuticals (VRTX 1.26%) during its IPO [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":13643,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":1,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142,240],"tags":[],"class_list":["post-13642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","category-stock-market","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance<\/title>\n<meta name=\"description\" content=\"The market wasn&#x27;t impressed by its latest quarterly update.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"The market wasn&#x27;t impressed by its latest quarterly update.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-09T16:40:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-09T16:40:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Henry Caldwell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/\"},\"author\":{\"name\":\"Henry Caldwell\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/ce4e0018708975682cf65487fee423ef\"},\"headline\":\"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now?\",\"datePublished\":\"2026-05-09T16:40:32+00:00\",\"dateModified\":\"2026-05-09T16:40:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/\"},\"wordCount\":660,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1\",\"articleSection\":[\"Finance &amp; Business\",\"Stock Market\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/\",\"name\":\"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1\",\"datePublished\":\"2026-05-09T16:40:32+00:00\",\"dateModified\":\"2026-05-09T16:40:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/ce4e0018708975682cf65487fee423ef\"},\"description\":\"The market wasn&#x27;t impressed by its latest quarterly update.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1\",\"width\":1200,\"height\":800,\"caption\":\"Vertex Pharmaceuticals logo.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/ce4e0018708975682cf65487fee423ef\",\"name\":\"Henry Caldwell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/gaa-0-henry-caldwell-fal.jpg\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/gaa-0-henry-caldwell-fal.jpg\",\"contentUrl\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/gaa-0-henry-caldwell-fal.jpg\",\"caption\":\"Henry Caldwell\"},\"description\":\"Henry Caldwell is an insightful author and contributor to the Oxford Wise Finance blog, where he shares his expertise on a wide array of general topics, with a particular focus on finance. With a background in economics and a passion for making complex concepts accessible, he engages readers with practical advice and thought-provoking analysis. Henry's writing empowers individuals to navigate the financial landscape with confidence, making informed decisions that enhance their financial literacy and overall well-being.\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/henry-caldwell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance","description":"The market wasn&#x27;t impressed by its latest quarterly update.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/","og_locale":"en_US","og_type":"article","og_title":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance","og_description":"The market wasn&#x27;t impressed by its latest quarterly update.","og_url":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/","og_site_name":"Blog - Oxford Wise Finance","article_published_time":"2026-05-09T16:40:32+00:00","article_modified_time":"2026-05-09T16:40:39+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","type":"image\/png"}],"author":"Henry Caldwell","twitter_card":"summary_large_image","twitter_misc":{"Written by":false,"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/"},"author":{"name":"Henry Caldwell","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/ce4e0018708975682cf65487fee423ef"},"headline":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now?","datePublished":"2026-05-09T16:40:32+00:00","dateModified":"2026-05-09T16:40:39+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/"},"wordCount":660,"commentCount":0,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","articleSection":["Finance &amp; Business","Stock Market"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/","url":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/","name":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now? - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","datePublished":"2026-05-09T16:40:32+00:00","dateModified":"2026-05-09T16:40:39+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/ce4e0018708975682cf65487fee423ef"},"description":"The market wasn&#x27;t impressed by its latest quarterly update.","breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","width":1200,"height":800,"caption":"Vertex Pharmaceuticals logo."},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/millionaire-maker-biotech-stock-is-it-a-smart-buy-now\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Millionaire-Maker Biotech Stock: Is It a Smart Buy Now?"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/ce4e0018708975682cf65487fee423ef","name":"Henry Caldwell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/01\/gaa-0-henry-caldwell-fal.jpg","url":"https:\/\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/01\/gaa-0-henry-caldwell-fal.jpg","contentUrl":"https:\/\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/01\/gaa-0-henry-caldwell-fal.jpg","caption":"Henry Caldwell"},"description":"Henry Caldwell is an insightful author and contributor to the Oxford Wise Finance blog, where he shares his expertise on a wide array of general topics, with a particular focus on finance. With a background in economics and a passion for making complex concepts accessible, he engages readers with practical advice and thought-provoking analysis. Henry's writing empowers individuals to navigate the financial landscape with confidence, making informed decisions that enhance their financial literacy and overall well-being.","url":"https:\/\/oxfordwisefinance.com\/blog\/author\/henry-caldwell\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2026\/05\/Is-This-Millionaire-Maker-Biotech-Stock-a-Buy-Right-Now.pngw1200opresize.png?fit=1200%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/13642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=13642"}],"version-history":[{"count":4,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/13642\/revisions"}],"predecessor-version":[{"id":13683,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/13642\/revisions\/13683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/13643"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=13642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=13642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=13642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}